Wearable drug delivery developer EOFlow has partnered automated diabetes treatment provider Diabeloop. The two companies will bring an automated insulin delivery (AID) system that will connect EOFlow’s wearable insulin pump EOPatch, a third-party continuous glucose monitoring (CGM) device and Diabeloop’s automated insulin delivery (AID) algorithm integrated in the Diabeloop’s smartphone app. The Companies also plan to integrate the EOPatch insulin pump into the DBLG1 System of Diabeloop, integrating the algorithm in a dedicated handset.

According to the Companies, the AID is developed by incorporating the algorithm ‘DBLG1’, the wearable insulin pump ‘EOPatch’ and a third-party CGM, which all have already received CE markings, and could be proposed to patients soon after the development has been completed. Commercial launch in Europe is expected from the end of 2023.

Diabeloop is currently collaborating or in discussion with several device manufacturers and is developing its smartphone app. EOFlow is considered a good match by Diabeloop as the company has a disposable, tubeless insulin pump solution and experience with diabetes condition management through apps.

EOFlow officially launched its tubeless, wearable, and disposable insulin pump ‘EOPatch’ in Korea and in Europe (by its European partner, A. Menarini Diagnostics with its GlucoMen Day brand) with its smartphone application ‘Narsha’ registered on Google Play Store and Apple AppStore. Narsha is the first app in the world for smartphones that allows users to monitor and control the wearable insulin pump. With the convenience and discretion it offers, Narsha is attracting a lot of new and potential pump users in Europe.

“In the field of automated insulin delivery, the adaptability and scalability of our wearable insulin pump is limitless, and we are working toward placing ourselves in a leadership position,” said Mr. Jesse J. Kim, EOFlow’s founder and CEO. “While we continue to commercialise EOPatch X, our artificial pancreas solution, we’re excited to kick off this partnership with Diabeloop and bring a wearable AID option to users sooner. We are also eager to make the smartphone app available in the European market.”

“It is an honour to partner with EOFlow and combine our state-of-the-art automated insulin delivery algorithm with their innovative wearable insulin pump solution. Diabeloop and EOFlow share the same goal to offer choices to people living with diabetes by providing advanced and user-friendly solutions. We confirmed the technical feasibility of our integration through a Hackathon last summer, and we are expanding this as an official development agreement to commercialise a combined solution,” said Erik Huneker, co-founder and CEO of Diabeloop.